Table 2.
Univariate analysis of antibody response rate in cancer patients after two BNT162b2 vaccinations (n = 172)
| Variable | Category | Serological response, n (%) |
P value | Odds ratio | |
|---|---|---|---|---|---|
| Positive | Negative | ||||
| Age | |||||
| <65 years | 74 (87.1) | 11 (12.9) | 1.0 | 1.03 (0.42-2.5) | |
| ≥65 years | 76 (87.4) | 11 (12.9) | |||
| Sex | |||||
| Male | 62 (83.8) | 12 (16.2) | 0.26 | 1.70 (0.69-4.21) | |
| Female | 88 (89.8) | 10 (10.2) | |||
| Time from vaccination | |||||
| <4 weeks | 2 (66.7) | 1 (33.3) | 0.28 | 3.52 (0.30-40.6) | |
| ≥4 weeks | 148 (87.6) | 21 (12.4) | |||
| Cancer status | |||||
| Early | 47 (82.5) | 10 (17.5) | 0.20 | 0.55 (0.20-1.36) | |
| Metastatic | 103 (89.6) | 12 (10.4) | |||
| Treatment | |||||
| Any treatment | |||||
| Yes | 119 (85.6) | 20 (14.4) | 0.20 | 0.38 (0.90-1.73) | |
| No | 31 (93.9) | 2 (6.1) | |||
| Chemotherapy | |||||
| Yes | 62 (77.5) | 18 (22.5) | <0.001 | 6.39 (2.06-19.8) | |
| No | 88 (95.7) | 4 (4.3) | |||
| Biological | |||||
| Yes | 34 (87.2) | 5 (12.8) | 1.0 | 1.03 (0.35-2.92) | |
| No | 116 (87.2) | 17 (12.8) | |||
| Hormonal | |||||
| Yes | 9 (90.0) | 1 (10.0) | 0.78 | 0.75 (0.09-6.19) | |
| No | 141 (87.0) | 21 (13.0) | |||
| Immunotherapy | |||||
| Yes | 42 (91.3) | 4 (8.7) | 0.33 | 0.57 (0.18-1.80) | |
| No | 108 (85.7) | 18 (14.3) | |||
| Best supportive care | |||||
| Yes | 3 (75.0) | 1 (25.5) | 0.46 | 2.33 (0.23-23.5) | |
| No | 147 (87.5) | 21 (12.5) | |||